Vocabria
(cabotegravir) GlaxoSmithKline limited
• Vocabria, a long-acting formulation of integrase strand transfer inhibitor, is administered as an intramuscular injection every 8 weeks. Vocabria has potent antiretroviral activity, in that very few HIV infections were observed in the Vocabria group during the injection phase of the study.3
• HIV infection risk was 88% lower in the Vocabria group, showing superiority over TDF-FTC in preventing HIV in this population.3
Reference:
3. Delany-Moretlwe et al. Lancet. 2022 May 7; 399(10337): 1779–1789.
